You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine

    SBC: 490 BIOTECH INC            Topic: 400

    Expressing humanized bacterial luciferase in stem cellsMoving beyond firefly luciferase toexpand the informational capacity of animal models for regenerative medicine Project Summary This Small Business Technology TransferSTTRPhase II project proposes to develop complementary autonomously bioluminescentautobioluminescentin vitro stem cell lines and in vivo small animal model systems that enable th ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Cuff Electrodes with Soft Wire Electrical Leads

    SBC: TDA RESEARCH, INC.            Topic: 102

    Project Summary AbstractDevelopment of a Nerve Cuff Electrode from Soft and Elastomeric Conducting Wires STTR Phase I ApplicationPIBrady ClapsaddleTDA ResearchIncBio electronic interfaces are used in a wide array of applications for recording and providing electrical impulses to treat diseaseOne common interface device for the PNS is the cuff electrodeCurrent cuff electrodes have many failure mode ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.

    SBC: BIOMIMETIX JV LLC            Topic: 102

    Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Clinical Screening Platform for Type Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    Abstract A major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to disease Current criteria involve HLA haplotype and the presence of auto antibodies AA Genome wide associated studies GWAS revealed only immune associated genes including HLA as T D predictors The ability to differentiate from other diseases was very limited Pre type diabetes p T ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke

    SBC: TRANSLATIONAL SCIENCES INC            Topic: NHLBI

    Seventeen million people each year suffer from an ischemic stroke and millions are left dead and disabledTreatment with recombinant tissue plasminogen activatorr tPAis only modestly effective at reducing disability and it is associated with brain hemorrhage in up toof patients when serial imaging studies are performedBrain hemorrhage causes death and disability andis the major cause of early morta ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Fully Human Antibodies for the Prevention of Respiratory Syncytial Virus

    SBC: IDBIOLOGICS INC            Topic: NIAID

    The goal of this STTR is to provide a preclinically validated monoclonal antibody or antibody combination for the prevention of respiratory syncytial virusRSVin high risk patients including infants and the elderlyWorldwideof children are infected with RSV before the age ofresulting in an estimatedmillion lower respiratory tract infectionsIn the United States adults overhavemillion RSV infections c ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Novel Clinical Diagnostic Assay for Peripheral T-cell Lymphoma (PTCL)

    SBC: HEALTHCHART LLC            Topic: 102

    Project Summary Abstract Peripheral T cell lymphomaPTCLis a heterogeneous cancer that constitutes up toof all non Hodgkin lymphomaNHLThe World Health Organization classification recognizes a number of distinct subtypes of PTCL but the diagnosis of these different subtypes is challenging even for expert hematopathologistsFurthermoreof PTCL cases are not classifiable into any specific subtype at all ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Screening for the autoimmune component of multiple sclerosis

    SBC: Op-T-Mune, Inc            Topic: NIAID

    Multiple Sclerosis is an inflammatory neurodegenerative disease with autoimmune components that exacerbate and potentially initiate the disease Diagnosis is invasive time consuming relatively expensive and extremely difficult In fact no clear diagnostic test yet exist A major concern is that MS symptoms are identical to the symptoms of numerous other neurologic diseases OND as well as some ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Developing a small peptide to control autoimmune inflammation in type diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    Abstract Type Diabetes T D affects an ever growing population While this disease typically has been associated with juveniles the disease in adult populations is rapidly increasing The defining clinical component is insulin loss which occurs because of sustained inflammation in the islets At present there is no means to prevent or reverse insulin loss A major inflammatory pathway in T D ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Fully Human Antibody Combinations for the Prevention of Seasonal Influenza Infection

    SBC: IDBIOLOGICS INC            Topic: NIAID

    Our overarching goal is to develop a monoclonal antibody based product for the prevention of seasonal influenza in high risk patientsIt is estimated there aredeaths annually related to seasonal influenza worldwideIn the United Statestheinfluenza season was classified a high severity season withdeathsandhospitalizations attributed to influenzaserving as a reminder of the continued severity of influ ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government